Routine CMO departure with replacement search underway — no immediate trading signal. Monitor for the new CMO appointment and any potential impact on clinical trial timelines or pipeline strategy. The separation agreement will be filed with the next 10-Q (quarter ending June 30, 2026) for full terms.
Price Chart
Executive Summary
Arvinas (ARVN) filed an 8-K announcing the departure of Chief Medical Officer Dr. Noah Berkowitz, effective July 3, 2026, with a search for a replacement underway. The departure is described as voluntary to pursue other opportunities, with standard severance including 9 months base salary and accelerated vesting of RSUs through May 9, 2027. This is a routine officer departure for a biotech company — the CMO role is important but not a CEO/CFO-level exit, and the filing lacks any financial data or guidance changes.
Key Facts
- Chief Medical Officer Dr. Noah Berkowitz departing July 3, 2026
- Departure described as voluntary to pursue other opportunities
- Search for replacement CMO has begun
- Severance: 9 months base salary continuation + up to 9 months health coverage
- Accelerated vesting of RSUs that would vest on or before May 9, 2027; all other RSUs forfeited
- Separation agreement includes standard release, confidentiality, and non-disparagement
Financial Impact
No material financial impact disclosed — severance is standard for a C-level officer departure at a ~$500M market cap biotech
Risk Factors
- Potential clinical development disruption if CMO replacement is delayed
- No financial or guidance data in this filing — limited read-through
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-044627 |
| Document: 0001628280-26-044627-index-headers.html | 0001628280-26-044627 |
| Document: 0001628280-26-044627-index.html | 0001628280-26-044627 |
| Document: 0001628280-26-044627.txt | 0001628280-26-044627 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 144 | $9.08 $8.26 | ▼ −9.03% | ▼ −7.91% | $7.41 (−18.39%) |
Jun 22, 2026 14w ago | 8-K | $8.14 $8.29 | ▲ +1.84% | ▲ +0.83% | $7.41 (−8.97%) |
Jun 2, 2026 17w ago | 8-K | $7.70 $6.98 | ▲ +9.35% | ▲ +5.53% | $7.41 (+3.77%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | Press Release | $9.57 $8.78 | ▲ +8.26% | ▲ +8.33% | $7.41 (+22.57%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 5, 2026 21w ago | Press Release | $10.61 $9.57 | ▲ +9.80% | ▲ +11.79% | $7.41 (+30.16%) |
May 1, 2026 22w ago | 8-K | $10.51 $10.19 | ▼ −3.04% | ▼ −5.39% | $7.41 (−29.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access